CASI: CASI Pharmaceuticals Inc. Market Cap to Revenue

Symbol and logo of brand casipharmaceuticals.com (CASI)

CASI Pharmaceuticals operates within the strict regulatory frameworks of the FDA and NMPA, where market access is limited by the high cost of development. The company's revenues are based on the sale of foreign oncology drugs in China. This GURU.Markets chart of the company's P/S ratio demonstrates that the metric has reached the level of 0.10. Patent protection and stable demand for medications guarantee a sustainable cash flow.

Price-to-Revenue Ratio: CASI Pharmaceuticals, Inc (CASI) for 07/04/2022 - 02/28/2026

CASI Pharmaceuticals (CASI) - metric breakdowns and financial figures

- stock price and consensus target price:
Share Price casipharmaceuticals.com|CASI - Analyst Consensus Forecast
- market capitalization information:
Market Valuation CASI|CASI - Enterprise Value
- book value of equity indicators:
Book Value per Share CASI Pharmaceuticals|CASI - Company Book Value|Market Capitalization to Book Value casipharmaceuticals.com|CASI - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Capital Coefficient CASI Pharmaceuticals|CASI - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital casipharmaceuticals.com|CASI - Company Debts|Debts to Book Capitalization Ratio CASI|CASI - Company Long-Term Debts|Company Short-Term Loans and Borrowings CASI Pharmaceuticals|Quick Ratio casipharmaceuticals.com
- company profitability and valuation multiples indicators:
CASI - Company Net Income|Expected Net Income CASI Pharmaceuticals|CASI - Price to Earnings Ratio|Projected Price to Earnings casipharmaceuticals.com|CASI - PEG Multiple|EV/EBITDA Multiple CASI|CASI - Operating profit EBITDA|Net earnings per share for the last 12 months CASI Pharmaceuticals|CASI - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months casipharmaceuticals.com|CASI - Net earnings per share growth this year|Earnings growth forecast for next year CASI Pharmaceuticals
- total revenue and sales volume data:
CASI - Company Sales|Company Projected Revenue Volume casipharmaceuticals.com|CASI - P/S Multiple|Market Cap to Expected Sales Ratio CASI
Fundamental company analysis:CASI Pharmaceuticals Inc. - CASI
Core merchandise of CASI Pharmaceuticals, Inc.

Fundamental metrics allow for the minimization of investment risks by eliminating emotional factors from valuation. For CASI Pharmaceuticals, which introduces Western hematological drugs to the Chinese market, capitalization transparency relative to actual sales is critical. By analyzing the company's P/S ratio, an investor sees the relationship between market price and revenue, which objectively links the stock value to cash flow. The P/S dynamics for CASI Pharmaceuticals reveal historical anomalies, helping to determine the fair value of the business.

Competing companies

tgtherapeutics.com - Market Cap to Revenue Ratio|P/S Multiple ACLX (Arcellx, Inc.)|IRON - Market Cap to Revenue|Syndax - P/S Multiple|KURA - P/S Multiple|ADC Therapeutics (ADCT) - Price-to-Revenue Ratio|FHTX - Price-to-Revenue Coefficient|VOR (Vor Biopharma) - P/S Multiple|Nkarta Corp (NKTX) - Price-to-Revenue Coefficient|Market Cap to Revenue COEP (Coeptis Therapeutics)|ATNM (Actinium Corp) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Estrella Immunopharma ESLA|MRKR (Marker Therapeutics Inc) - Price-to-Sales Ratio|IN8bio - P/S Multiple|Market Capitalization-to-Revenue Ratio ERNA (Eterna Therapeutics)|GTBP: P/S Multiple|Aptose Biosciences (APTO) - P/S Multiple|Price-to-Revenue Ratio Bio-Path Holdings|MEIP: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Vincerx Pharma, Inc. (VINC)